NCT06454630View on ClinicalTrials.gov

A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants

PHASE2CompletedINTERVENTIONAL
Enrollment

179

Participants

Timeline

Start Date

June 27, 2024

Primary Completion Date

January 21, 2025

Study Completion Date

January 21, 2025

Conditions
Venous Thromboembolism
Interventions
DRUG

REGN7508

Administered by single intravenous (IV) dose

DRUG

Enoxaparin

Administered by subcutaneous (SC) dose daily through the time of venography (or day 12, whichever is earlier)

Trial Locations (14)

1027

Budai Irgalmasrendi Korhaz, Budapest

4002

Multiprofile Hospital For Active Treatment Park Hospital Ltd., Plovdiv

5000

Szolnoki MAV Hospital, Szolnok

5800

Multi-profile Hospital for Active Treatment Hearth and Brain EAD, Pleven

LV-4201

Vidzemes Hospital, Valmiera

LV-3414

Liepaja Regional Hospital, Liepāja

LV-1004

Riga's 2nd Hospital, Riga

LV-1005

Hospital of Traumatology and Orthopaedics, Riga

Orto Klinika, Riga

LT-50161

Lietuvos sveikatos mokslu universiteto ligonine Kauno klinik, Kaunas

LT-48142

Lithuanian University of Health Sciences Kaunas Hospital, Kaunas

LT-92288

Klaipeda University Hospital, Klaipėda

33-100

Specjalistyczny Szpital im. E. Szczeklika w Tarnowie, Tarnów

92-213

Clinic of Orthopaedics and Paediatric Orthopaedics, Lodz

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY

NCT06454630 - A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants | Biotech Hunter | Biotech Hunter